Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026.

Furuya, Naoki; Fukuhara, Tatsuro; Saito, Haruhiro; Watanabe, Kana; Sugawara, Shunichi; Iwasawa, Shunichiro; Tsunezuka, Yoshio; Yamaguchi, Ou; Okada, Morihito; Yoshimori, Kouzou; Nakachi, Ichiro; Gemma, Akihiko; Azuma, Koichi; Hagiwara, Koichi; Nukiwa, Toshihiro; Morita, Satoshi; Kobayashi, Kunihiko; Maemondo, Makoto

doi:https://doi.org/10.1200/JCO.2018.36.15_suppl.9006

WEKO3

lat lon distance

[[sub_check.contents]]

[[sub_radio.contents]]

Field does not validate

[[sub_attr.contents]]　

インデックスツリー

アイテム

Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026.

https://iwatemed.repo.nii.ac.jp/records/2000774

アイテムタイプ

会議発表論文 / Conference Paper(1)

公開日

2024-11-07

タイトル

Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026.

言語

eng

資源タイプ

資源タイプ識別子

http://purl.org/coar/resource_type/c_5794

資源タイプ

conference paper

アクセス権

metadata only access

アクセス権URI

http://purl.org/coar/access_right/c_14cb

著者

Furuya, Naoki
Fukuhara, Tatsuro
Saito, Haruhiro
Watanabe, Kana
Sugawara, Shunichi
Iwasawa, Shunichiro
Tsunezuka, Yoshio
Yamaguchi, Ou
Okada, Morihito
Yoshimori, Kouzou
Nakachi, Ichiro
Gemma, Akihiko
Azuma, Koichi
Hagiwara, Koichi
Nukiwa, Toshihiro
Morita, Satoshi
Kobayashi, Kunihiko
Maemondo, Makoto

bibliographic_information

en : Journal of Clinical Oncology

巻 36, 号 15suppl, p. 9006, 発行日 2018-06

出版者

American Society of Clinical Oncology

言語

item_10003_source_id_9

収録物識別子タイプ

PISSN

収録物識別子

0732-183X

Versions

Ver.1

2024-11-12 02:48:40.819030

Show All versions

Cite as

Other

エクスポート

OAI-PMH

JPCOAR 2.0
JPCOAR 1.0
DublinCore
DDI

Other Formats

インデックスリンク

インデックスツリー

アイテム

Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026.

× Furuya, Naoki

× Fukuhara, Tatsuro

× Saito, Haruhiro

× Watanabe, Kana

× Sugawara, Shunichi

× Iwasawa, Shunichiro

× Tsunezuka, Yoshio

× Yamaguchi, Ou

× Okada, Morihito

× Yoshimori, Kouzou

× Nakachi, Ichiro

× Gemma, Akihiko

× Azuma, Koichi

× Hagiwara, Koichi

× Nukiwa, Toshihiro

× Morita, Satoshi

× Kobayashi, Kunihiko

× Maemondo, Makoto

Versions

Share

Cite as

Other

エクスポート

コミュニティ

メニューを最小化

インデックスリンク

インデックスツリー

アイテム

Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026.

× Furuya, Naoki

× Fukuhara, Tatsuro

× Saito, Haruhiro

× Watanabe, Kana

× Sugawara, Shunichi

× Iwasawa, Shunichiro

× Tsunezuka, Yoshio

× Yamaguchi, Ou

× Okada, Morihito

× Yoshimori, Kouzou

× Nakachi, Ichiro

× Gemma, Akihiko

× Azuma, Koichi

× Hagiwara, Koichi

× Nukiwa, Toshihiro

× Morita, Satoshi

× Kobayashi, Kunihiko

× Maemondo, Makoto

Versions

Share

Cite as

Other

エクスポート

コミュニティ